Man Group
DYN icon

Man Group’s Dyne Therapeutics DYN Stock Holding History

Man Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95,682
Closed -$1.73M – 2409
2026
Q1 		$1.73M Buy
+95,682
New +$1.65M ﹤0.01% 1630
2025
Q1 		– Sell
-746,463
Closed -$17.6M – 2225
2024
Q4 		$17.6M Buy
746,463
+27,813
+4% +$823K 0.05% 481
2024
Q3 		$25.8M Buy
+718,650
New +$28.6M 0.07% 366

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Man Group's DYN Position: Q2 2026 in Review

Man Group sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 95,682 shares — an estimated $1.73M sold.

Man Group first reported a position in DYN in Q3 2024 and held it in 3 quarters. The position peaked at $25.8M in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Man Group reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 95,682 Dyne Therapeutics shares in Q2 2026, an estimated $1.73M.
  • Man Group first reported a position in Dyne Therapeutics in Q3 2024 and held it in 3 quarters.
  • Man Group's Dyne Therapeutics position peaked at $25.8M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.